However, our results showed that the resistance of melanoma to MitoX in vivo (but not in vitro, Figure 4 and Supplementary Figure S6) occurred due to tumor autophagic activity, since tumor autophagy inhibition by Becn1 silencing overcame chemoresistance to MitoX treatment and induced a tumor-suppressive immune microenvironment (Figure 4). This evidence concerns the gene BECN1 and neoplasm.